Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Amgen Ratings: Sell and Buy Targets Clash at $230-$452

Guavy AI Editorial Team
Instruments
AMGN
Share

Major Wall Street analysts have updated their ratings for Amgen (AMGN.US), with price targets ranging from $230 to $452. BofA Securities analyst Tazeen Ahmad maintains a sell rating and adjusts the target price from $312 to $317.

UBS analyst Michael Yee maintains a buy rating and adjusts the target price from $420 to $440.

TD Cowen analyst Yaron Werber also maintains a buy rating, with a target price of $452.

Baird analyst Brian Skorney keeps his sell rating and lowers the target price to $230, while Oppenheimer analyst Jay Olson adjusts his target price from $400 to $450.

More on Stocks

Stocks just now

Swiss Government Office Hit with SharePoint Breach

Stocks just now

Phishing Campaign Compromises Microsoft 365 Accounts Using AiTM Techniques

Stocks just now

Microsoft Teams Up with SMRU Consulting to Develop AI-Powered Whale Conservation Tech

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy